GLP-1 receptor agonists before conception: no clear signal, no proof of safety

Design

Systematic review and random-effects meta-analysis of 10 observational studies

Population

2,118,215 women; 8,325 exposed to GLP-1 receptor agonists within 6 months before a positive pregnancy test

Primary outcome

Miscarriage, intrauterine death, congenital anomalies, preterm birth and other maternal and perinatal outcomes

Effect

No clearly detectable increase in adverse outcomes; pre-eclampsia OR 0.87 (95% CI 0.78 to 0.98) from two datasets

This systematic review and meta-analysis pooled ten observational studies including 2,118,215 women, of whom 8,325 had been exposed to a GLP-1 receptor agonist within 6 months before a positive pregnancy test.

Pooled estimates did not show a clearly detectable increase in miscarriage, intrauterine death, congenital anomalies, preterm birth, hypertensive disorders of pregnancy, gestational diabetes, abnormal fetal growth or excess gestational weight gain. A lower pooled estimate for pre-eclampsia appeared (OR 0.87, 95% CI 0.78 to 0.98), but it rested on two datasets and the authors advise caution.

The authors state plainly that the findings do not establish safety, because of heterogeneity, residual confounding and limited datasets. Exposed numbers are small relative to the comparison group.

This helps counselling for women who conceive unexpectedly on treatment. It is not a reason to change the advice to plan pregnancy and review the medicine beforehand.

• Ask women of reproductive age on GLP-1 therapy about contraception and pregnancy plans.
• If conception occurs on treatment, reassurance is reasonable that pooled observational data show no clear excess of adverse outcomes, with the caveat that safety is unproven.
• Do not use the pre-eclampsia estimate to justify treatment; it came from two datasets.
• Document the exposure window, since the analysis used treatment within 6 months before a positive test.

Why it matters

It gives a more evidence-based answer to the common question of what to say after an unplanned pregnancy on a GLP-1 drug.

Don't overread it

Observational pooling cannot separate drug effects from maternal obesity or diabetes, and the authors say safety is not established.

The statistics, in plain English

An odds ratio of 0.87 with an interval of 0.78 to 0.98 only just excludes 1.0. With two datasets behind it, a small shift in either could erase it. Absence of a detectable increase is also weaker than evidence of no increase when exposed numbers are small.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.